Quarterly report · Q3
3055.TEDINET S100SUQB
Period2023-04-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥209.2bn | 2023-04-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥262.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥199.1bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | ¥2.4bn | 2023-04-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | ¥2.7bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | ¥2.9bn | 2023-04-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥3.9bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.2bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥2.9bn | 2023-04-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥3.6bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.8bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.4bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.8bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | ¥2.4bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥151.9bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥137.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥146.6bn | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥92.6bn | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥80.5bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥59.3bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥57.4bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥57.6bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥19.5bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥18.0bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥19.5bn | at 2023-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥18.0bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥21.4bn | at 2022-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥21.1bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥4.5bn | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥828m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.0bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥2.2bn | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥856m | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥865m | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥835m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥808m | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥82.9 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥49.9 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥123.41 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥109.94 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥46.72 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 39.0% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.6% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.3% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 56
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2023-04-01 → 2023-12-31 | ¥1.6bn |
| Otherother segments | revenue external | 2023-04-01 → 2023-12-31 | ¥44m |
| Otherother segments | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥1.5bn |
| Otherother segments | segment profit | 2023-04-01 → 2023-12-31 | ¥516m |
| jpcrp040300-q3r_E03003-000Dispensing Industryreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥10.1bn |
| jpcrp040300-q3r_E03003-000Dispensing Industryreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥10.1bn |
| jpcrp040300-q3r_E03003-000Dispensing Industryreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥9m |
| jpcrp040300-q3r_E03003-000Dispensing Industryreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥113m |
| jpcrp040300-q3r_E03003-000Information And Communication Technology Industryreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥1.2bn |
| jpcrp040300-q3r_E03003-000Information And Communication Technology Industryreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥369m |
| jpcrp040300-q3r_E03003-000Information And Communication Technology Industryreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥794m |
| jpcrp040300-q3r_E03003-000Information And Communication Technology Industryreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥48m |
| jpcrp040300-q3r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥49.0bn |
| jpcrp040300-q3r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥48.6bn |
| jpcrp040300-q3r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥401m |
| jpcrp040300-q3r_E03003-000Medical Equipment Wholesale Industryreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥911m |
| jpcrp040300-q3r_E03003-000Nursing Industryreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥3.1bn |
| jpcrp040300-q3r_E03003-000Nursing Industryreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥3.1bn |
| jpcrp040300-q3r_E03003-000Nursing Industryreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥3m |
| jpcrp040300-q3r_E03003-000Nursing Industryreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥217m |
| jpcrp040300-q3r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥153.6bn |
| jpcrp040300-q3r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥146.9bn |
| jpcrp040300-q3r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥6.7bn |
| jpcrp040300-q3r_E03003-000Wholesaler Of Drugs Industryreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥1.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-12-31 | ¥218.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-12-31 | ¥209.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥9.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-12-31 | ¥3.1bn |
| Otherother segments | revenue | 2022-04-01 → 2022-12-31 | ¥1.9bn |
| Otherother segments | revenue external | 2022-04-01 → 2022-12-31 | ¥46m |
| Otherother segments | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥1.8bn |
| Otherother segments | segment profit | 2022-04-01 → 2022-12-31 | ¥819m |
| jpcrp040300-q3r_E03003-000Dispensing Industryreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥10.2bn |
| jpcrp040300-q3r_E03003-000Dispensing Industryreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥10.2bn |
| jpcrp040300-q3r_E03003-000Dispensing Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥9m |
| jpcrp040300-q3r_E03003-000Dispensing Industryreportable segment | segment profit | 2022-04-01 → 2022-12-31 | −¥14m |
| jpcrp040300-q3r_E03003-000Information And Communication Technology Industryreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥1.2bn |
| jpcrp040300-q3r_E03003-000Information And Communication Technology Industryreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥362m |
| jpcrp040300-q3r_E03003-000Information And Communication Technology Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥825m |
| jpcrp040300-q3r_E03003-000Information And Communication Technology Industryreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥25m |
| jpcrp040300-q3r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥49.2bn |
| jpcrp040300-q3r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥48.9bn |
| jpcrp040300-q3r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥379m |
| jpcrp040300-q3r_E03003-000Medical Equipment Wholesale Industryreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.1bn |
| jpcrp040300-q3r_E03003-000Nursing Industryreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥3.0bn |
| jpcrp040300-q3r_E03003-000Nursing Industryreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥3.0bn |
| jpcrp040300-q3r_E03003-000Nursing Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥2m |
| jpcrp040300-q3r_E03003-000Nursing Industryreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥295m |
| jpcrp040300-q3r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥143.5bn |
| jpcrp040300-q3r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥136.6bn |
| jpcrp040300-q3r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥6.9bn |
| jpcrp040300-q3r_E03003-000Wholesaler Of Drugs Industryreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-12-31 | ¥209.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-12-31 | ¥199.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥9.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-12-31 | ¥3.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 517
| Item | Context | Value | Unit |
|---|---|---|---|
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated statement of cash flows (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding promissory notes due on balance sheet date (text) | CurrentQuarterInstant | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Description of nature of differences between profit loss of reportable segments total and quarterly financial statements (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Description of nature of differences between profit loss of reportable segments total and quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |